RXi Pharmaceuticals and MirImmune have entered into an exclusive license agreement for RXi’s novel and proprietary sd-rxRNA technology for use in developing innovative cell-based cancer immunotherapies. The collaboration has the potential to result in novel, more effective and patient friendly cancer treatments that could be a significant step toward personalized medicine. Under the terms of the agreement, MirImmune will be responsible for all research, development, manufacturing, regul...